Novel oncology approvals by the US Food and Drug Administration continue to come in fast and furious. With the approvals of Eli Lilly & Co.’s Retevmo and Novartis AG’s Tabrecta last week, the agency has cleared nine new molecular entities or novel biologics for cancer treatment in 2020 to date, making up half of the year’s novel approvals.
Even more striking is the speed of the oncology reviews
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?